多omics整合确定ASPH和PTTG1作为肺腺癌进展和免疫逃避的潜在因果驱动因素
Kai Yang1,2,3, MeiFeng Chen2,4, Yao Wu2,4
1Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Frontiers in immunology
|November 28, 2025
概括
研究人员确定了阿斯巴酸β-基酶 (ASPH) 和垂体瘤转化基因1 (PTTG1) 作为肺腺癌 (LUAD) 血管生成和免疫规避的关键调节者. 这些基因可以作为有前途的生物标志物和精准医学的治疗点.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 免疫学 免疫学 免疫学
背景情况:
- 肺腺癌 (LUAD) 是癌症死亡的主要原因,血管新生和免疫逃避显著影响进展和治疗耐药性.
- 在LUAD中表皮衍生的调节机制和因果基因仍然不完全理解.
研究的目的:
- 用单细胞转录组学在LUAD中识别表皮特异性,血管生成相关的基因.
- 为了确定 LUAD 中识别的基因的遗传因果关系和预后意义.
- 探索这些基因在瘤免疫微环境中的作用及其作为治疗点的潜力.
主要方法:
- 单细胞RNA测序 (scRNA-seq) 用于识别LUAD上皮细胞中的血管生成相关基因.
- 孟德尔随机化 (MR) 分析使用大规模的基因组数据库来确定遗传因果关系.
- 使用癌症基因组图谱 (TCGA) 和基因表达综合 (GEO) 队列开发和验证预后风险模型.
- 功能性测试包括基因敲除,增殖,迁移,入侵测试和西方抹杀,以验证基因功能和蛋白质表达.
主要成果:
- 亚斯巴酸β-基酶 (ASPH) 和垂体瘤转化基因1 (PTTG1) 被确定为与LUAD风险和不良预后相关的因果基因.
- 在LUAD组织中证实了ASPH和PTTG1蛋白表达的升高,ASPH敲击抑制了LUAD细胞的增殖,迁移和入侵.
- ASPH/PTTG1风险模型准确预测了预后. 高风险患者表现出"寒冷"的免疫微环境和对西斯普拉丁和克里佐替尼布的敏感性增加.
结论:
- ASPH和PTTG1是LUAD血管生成和免疫逃避的关键调节者,通过综合单细胞测序,MR因果关系和功能验证来确定.
- ASPH和PTTG1代表了LUAD有前途的生物标志物和治疗点.
- 这些发现为开发精确疗法提供了洞察力,这些疗法结合了抗血管原和免疫调节策略,用于LUAD治疗.
更多相关视频
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
2.1K
07:39The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues
Published on: June 16, 2018
9.8K
相关概念视频
02:53Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
02:07Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K